Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Autonomic Testing Coverage & Prior Auth …
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy MP327

    Autonomic Testing

    Customize your policy alerts

    Sign up for Geisinger Health Plan Policy MP327 alerts

    Get alerted when Policy MP327 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, coverage stance, exclusions, and coding guidance for autonomic nervous system testing for Geisinger Health Plan members across commercial, Medicare, CHIP, and Medicaid lines of business.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyAutonomic Testing
    Policy CodePolicy MP327
    Change TypeNo material clinical or coverage changes indicated
    Effective DateJul 19, 2024
    Next Review Date
    Key ActionVerify member benefits and obtain prior authorization when required; document the specific autonomic testing performed and the clinical indication.
    SourceLink
    9CPT codes listed
    10medically necessary indications
    14exclusions/unproven items
    annual reviewpolicy review cadence
    may applyprior auth referenced

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Autonomic Testing

    Medically necessary indications

    Autonomic testing is considered medically necessary in the evaluation of any of the following conditions:

    Indications list: Diagnose the presence of autonomic neuropathy when signs or symptoms suggest a progressive autonomic neuropathy (including, but not limited to: diabetic neuropathy; amyloid neuropathy; Sjögren's syndrome; idiopathic neuropathy; pure autonomic failure; multiple system atrophy).

    Each bulleted clinical indication is sufficient to consider testing as medically necessary per the policy.

    Indications list: Evaluate orthostatic hypotension in a member with dizziness, a drop in blood pressure, or syncope upon standing.
    Indications list: Differentiate certain complicated variants of syncope from other causes of loss of consciousness.
    Indications list: Evaluate the severity and distribution of a diagnosed progressive autonomic neuropathy.
    Indications list: Diagnose and differentiate the cause of postural tachycardia syndrome.
    Indications list: Evaluate change in type, distribution or severity of autonomic deficits in members with autonomic failure.
    Indications list: Diagnose axonal neuropathy or suspected autonomic neuropathy in the symptomatic member.
    Indications list: In central neurodegenerative disorders, especially the synucleinopathies, distinguish multiple system atrophy from Parkinson's disease and diffuse Lewy body disease.

    Quantitative pupillometry/pupillography (for example, the NeurOptics NPi-100 Pupillometer) is explicitly considered unproven and NOT COVERED. The policy states there is insufficient evidence in the published, peer‑reviewed medical literature to support the clinical use of these hand‑held infrared pupillometry devices, and therefore they are excluded from coverage.

    More broadly, the policy emphasizes that autonomic testing performed using automated devices with software‑generated interpretations (examples listed include ANSAR ANX 3.0, SUDOSCAN, VitalScan, Neuropad, EZScan, and electrochemical skin conductance [ESC]) lacks validation and is likewise considered unproven and NOT COVERED.

    Providers should note that these exclusions sit alongside the plan’s general exclusions for experimental, investigational, or unproven services as described in member certificates; benefit‑specific limits and prior authorization requirements may still apply and supersede this policy where indicated.

    Coverage excludes services, procedures, and technologies that are determined to be experimental, investigational, or unproven under the member’s certificate. Unproven services delivered outside of an approved clinical trial are specifically excluded. This policy does not expand coverage to include items or services that are specifically excluded by the member’s contract.

    Providers should verify member eligibility and contract‑specific benefits prior to delivering services, since line‑of‑business coverage statements and applicable Medicare LCD/NCD guidance may supersede the policy and affect prior authorization requirements.

    In addition to quantitative pupillometry and automated interpretation devices, the policy lists other autonomic tests and uses that are considered not medically necessary / not covered because of insufficient evidence. These include the Quantitative pilomotor axon reflex test (QPART) and use of autonomic testing for the following conditions: myofascial pain syndrome/fibromyalgia, Raynaud’s phenomenon, predicting foot ulcers, flushing syndrome, chronic fatigue syndrome, generalized hyperhidrosis, palmoplantar hyperhidrosis, irritable bowel syndrome, somatization disorder, and anxiety disorder.

    The policy notes that these tests and indications lack adequate peer‑reviewed evidence to establish clinical value and are therefore excluded from coverage.

    During the most recent revision, the policy was updated to add an explicit exclusion for quantitative pupillometry and to clarify unproven language for automated autonomic testing devices. The document states these techniques have insufficient supporting evidence and are therefore considered unproven and not covered.

    As with other exclusions, this revision reiterates that experimental, investigational, or unproven services remain excluded under the member’s certificate and that prior authorization and benefit‑specific rules may apply.

    Coding Related to Autonomic Testing

    CPT codes associated with autonomic testing (informational)CPT
    95919Quantitative pupillometry with physician or qualified health care professional interpretation and report, unilateral or bilateral
    95921Testing of autonomic nervous system function; cardiovagal innervation (parasympathetic function), including two or more of the following: heart rate response to deep breathing with recorded R-R interval, Valsalva ratio, and 30:15 ratio
    95922Vasomotor adrenergic innervation (sympathetic adrenergic function), including beat-to-beat blood pressure and R-R interval changes during Valsalva maneuver and at least 5 minutes of passive tilt
    95923sudomotor, including one or more of the following: quantitative sudomotor axon reflex test (QSART), silastic sweat imprint, thermoregulatory sweat test, and changes in sympathetic skin potential
    95924combined parasympathetic and sympathetic adrenergic function testing with at least 5 minutes of passive tilt
    95943Simultaneous, independent, quantitative measures of both parasympathetic function and sympathetic function, based on time-frequency analysis of heart rate variability concurrent with time-frequency analysis of continuous respiratory activity, with mean heart rate and blood pressure measures, during rest, paced (deep) breathing, Valsalva maneuvers, and head-up postural change

    Provider Actions, Authorization & Documentation

    Prior Authorization

    Verify benefits and prior authorization

    Verify member eligibility and contract-specific benefits, limitations, and exclusions before ordering autonomic testing; line-of-business benefit documents and applicable Medicare LCDs/NCDs supersede this policy.

    • Confirm member eligibility and benefits for the requested service.
    • Review the member's line-of-business benefit document for coverage statements that supersede this policy.
    • For Medicare members, verify applicable Local Coverage Determinations (LCDs) and National Coverage Determinations (NCDs).
    Prior Authorization

    Prior authorization requirement — check member benefit documents

    Prior authorization or precertification may be required for autonomic testing; check the member's contract specific benefit document and Geisinger prior authorization resources before performing services.

    • Consult the member's contract-specific precertification lists for prior authorization requirements.

    Background on Autonomic Testing

    Autonomic testing assesses multiple domains of autonomic nervous system function, typically grouped into cardiovagal (parasympathetic), vasomotor/adrenergic (sympathetic), and sudomotor evaluations. Commonly used tests include measures of heart rate variability and reflexes for cardiovagal function, blood pressure and R‑R interval responses for vasomotor/adrenergic function (including tilt testing and Valsalva), and quantitative sudomotor assessments such as QSART, thermoregulatory sweat testing, or other measures of sweat production.

    These tests are used to diagnose and assess the severity and distribution of autonomic neuropathies, evaluate orthostatic hypotension and syncope variants, help differentiate certain neurodegenerative synucleinopathies, and to evaluate conditions such as postural tachycardia syndrome when clinically indicated.

    Definitions

    Medical Necessity / Medically Necessary
    DefinitionCovered services that are appropriate for the symptoms and diagnosis, provided for diagnosis and direct care, aligned with current standards of good medical treatment, not primarily for convenience, and the most appropriate level of service that can safely be provided.
    StandardsMust be in accordance with current standards of good medical treatment practiced by the general medical community.
    LimitationsNot primarily for convenience of the member or provider; when hospitalization is involved, inpatient status requires that the member cannot receive safe or adequate care as an outpatient.
    Most actionable criterionA service is medically necessary only if it is appropriate for the symptoms and diagnosis and is the most appropriate level of service that can safely be provided (verify member-specific benefits).
    Autonomic testing — diagnostic procedures and examples
    Policy Summary
    PayerGeisinger Health Plan
    PolicyAutonomic Testing
    Policy CodePolicy MP327
    Change TypeNo material clinical or coverage changes indicated
    Effective DateJul 19, 2024
    Next Review Date
    Key ActionVerify member benefits and obtain prior authorization when required; document the specific autonomic testing performed and the clinical indication.
    SourceLink
    On This Page
    Coverage Criteria for Autonomic TestingCoding Related to Autonomic TestingProvider Actions, Authorization & DocumentationBackground on Autonomic TestingDefinitions
  1. Check Geisinger's provider prior authorization site: https://www.geisinger.org/health-plan/providers/ghp-clinical-policies
  2. Note

    Confirm medical indication and authorization before testing

    Document the clinical indication supporting the test and ensure benefit and authorization checks are completed prior to scheduling; verify that the requested test aligns with an accepted medically necessary indication per policy.

    • Record the specific clinical indication that makes autonomic testing medically necessary.
    • Confirm prior authorization/benefit verification was completed and documented in the patient record.
    Denial Risk

    Stop if member's benefit does not cover the service

    If the member's benefit document or line-of-business coverage statement does not cover the requested autonomic test, do not proceed without obtaining an authorization or alternate coverage — requests may be denied if not covered by the member's contract.

    • Coverage statements in the line-of-business benefit document supersede this policy; obtain authorization only if the benefit allows coverage.
    • For Medicare, ensure compliance with LCD/NCD coverage rules to avoid denials.
    Documentation Required

    Coding and documentation guidance — record CPT code and clinical indication

    Document the specific autonomic test(s) performed using CPT codes and the clinical indication in the medical record; the listed CPT codes are informational and inclusion does not guarantee coverage.

    • List the CPT code(s) that correspond to the test performed (e.g., 95921, 95922, 95923, 95924, 95943, 95919) in the report.
    • Include the clinical reason for testing and any supporting findings in the record.
    • Note that Medicare may only cover specific CPT codes per CMS rules; consult CMS or the local MAC for Medicare coding guidance.
    Prior Authorization

    Precertification / prior authorization — consult benefit document

    Consult the member's contract specific benefit document for any precertification/prior authorization requirements; prior authorization information is available on Geisinger's provider site.

    • Check precertification lists within the member's contract-specific benefit document.
    • Access Geisinger prior authorization resources: https://www.geisinger.org/health-plan/providers/ghp-clinical-policies
    Denial Risk

    Coverage limited by member benefit documents and Medicare rules

    Requests for autonomic testing may be denied if the member's certificate, line-of-business benefit document, or applicable Medicare LCD/NCD excludes the service — verify coverage prior to service.

    • Coverage statements in the line-of-business benefit document supersede this policy and may result in denial.
    • For Medicare members, applicable LCDs and NCDs will supersede this policy and can affect coverage determinations.
    Denial Risk

    Experimental, investigational, or unproven services are excluded

    Services that are experimental, investigational, or unproven are specifically excluded under the member's certificate; quantitative pupillometry and other listed unproven tests are not covered outside an approved clinical trial.

    • Quantitative pupillometry/pupillography (e.g., NeurOptics NPi-100 Pupillometer) and automated devices with software-generated interpretations are considered unproven and not covered.
    • Unproven services outside of an approved clinical trial are excluded per the member's certificate and policy MP015.
    Definition
    Diagnostic procedures that assess cardiovascular, sudomotor, pupillary, and other autonomic nervous system functions.
    Cardiovagal (parasympathetic) examplesHeart rate variability testing, response to deep breathing, Valsalva ratio, 30:15 ratio.
    Vasomotor adrenergic (sympathetic) examplesBlood pressure response to standing, Valsalva maneuver, hand grip testing, and head-up tilt (tilt table) testing.
    Sudomotor examplesQuantitative sudomotor axon reflex test (QSART), thermoregulatory sweat test (TST), quantitative sudomotor testing (QST), silastic sweat imprint.
    Pupillary testing exampleQuantitative pupillometry is listed in references as a pupillary assessment method (policy notes quantitative pupillometry as unproven/excluded).